Enrolling Now:  ABT-089
Men and women ages 55 to 90 are needed to participate in a research study of an investigational medication for Alzheimer’s disease.  Participants must be currently taking Aricept®, Exelon® or Razadyne®.  Health insurance is not required.

Qualified participants will receive at no cost

• Study medication
• Study related medical care
• Memory testing

Reimbursement for time and travel is available.
Contact Elaine Ziol at 216-844-6328 for more information.

Enrolling Now:  Home-Based Assessment
 This study will evaluate three in-home types of information gathering (telephone, electric kiosk, or mail-in forms) and determine how practical each method is.

To be included participants must be:
Age 75 or older

• Fluent in English
• Able to live independently
• Have normal mental function
• Be willing to take multi-vitamins provided by the study
• Be able to answer and dial a telephone, have access to secure mail, possess minimal computer skills or a willingness to learn.

Contact Susie Sami at 216-844-6351 for more information.

Enrolling Soon:

• RAGE Inhibitor
• AAB-001
• Intravenous Immunoglobulin
• Aricept SR

Who's Eligible to participate?

Your family is eligible to participate if they meet the following criteria:

• A living family member who has been diagnosed with Alzheimer's disease.
• The family member with AD has a living brother or sister (full sibling) who is willing to participate in the study.
• Eligible family members will be asked to complete a family medical history questionnaire.
• Patient and sibling will be asked to donate a small sample of blood, and MRI at the study's expense.

Study Participants receive:

• A magnetic resonance imaging (MRI) and summery report sent to your physician, if you wish
• Enrollment in the University Memory & Aging Center Research Registry.
• Monetary compensation for time and effort
• Confidential participation and access to a top area Neurologist and leader in Alzheimer's Research.

Mirage (Multi Institutional research in Alzheimer's Genetic Epidemiology) CWRU is one of thirteen sites funded for this project by the NIH - National Institute on Health.

The Caregiver Knowledge and Skills Project is a research study being conducted by the University Memory and Aging Center of Case Western University and University Hospitals Case Medical Center.  The goal of the study is to learn how best to help family members of persons with Alzheimer's disease or other types of dementia increase their knowledge and skills related to caregiving.

Participating caregivers will:

• Take part with other caregivers in six two-hour workshop sessions (one per week for 6 weeks), designed to provide knowledge and skills for family caregivers;
• read materials and practice what is learned in the workshop between the weekly sessions;
• take part in an 8-month follow-up program - either by mail or by computer - designed to extend and enhance benefits of the workshop, with the type of followup determined randomly.
• answer questions by mail about their well being and their experiences with the attitudes toward caregiving for times over the course of the study;
• be asked to give their opinions about the workshop and follow up programs when the study is completed.

There are no costs for participation and the study has been approved by the University Hospitals Case Medical Center Institutional Review Board.

If you are caring for someone with mild to moderate Alzheimer's disease or other type of dementia who is living at home, and would like to learn more about the Caregiver Knowledge and Skills Project, please call Nancy at 216-844-6357

UPCOMING RESEARCH

Study title: A 24-week, double-blind, double-dummy, randomized, parallel group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on congition and overall clinical response in APOE Î4-stratified subjects with mild to moderate Alzheimer's disease.

 Primary Objective

To investigate the effects of daily dosing for 24 weeks with RSG XR(extended release) versus donepezil or placebo on cognitive function and overall clinical response in subjects with mild to moderate Alzheimer's disease as a function of APOE Î4 status.

All study related medical exams, laboratory tests and study medications will be provided to qualifying participants at no cost.  Patient participation is anticipated to be approximately 32 weeks with 9 clinic visits.

CONTACT: Joy Kettren, MS (Study Coordinator) 216-445-0283